Raf and Mek Inhibitor Combination for RAS-Mutant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for RAS-mutant tumors, such as KRAS and NRAS mutant cancers, lack effective targeted treatments, with existing RAF and MEK inhibitors showing limited clinical activity and adverse side effects, and there is a need for therapies that provide durable and sustained responses with fewer adverse effects.
Innovation Solution
A pharmaceutical combination of a selective Raf inhibitor, such as Compound of formula (I) or Compound of formula (II), and a MEK inhibitor like trametinib, which potently inhibit BRAF and CRAF, demonstrating synergistic effects in blocking BRAF-mutant and RAS-mutant driven tumorigenesis, and showing increased anti-tumor responses in various cancer models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing RAF and MEK inhibitors are used for RAS-mutant tumors, then some therapeutic effect is achieved, but clinical activity is limited and adverse side effects occur
Solution Approach 1:
The patent combines a selective RAF inhibitor (Compound of formula (I) or (II)) with a MEK inhibitor (trametinib) to create a dual-target therapy. This combination approach merges the effects of two different inhibitors to achieve synergistic anti-tumor activity while potentially reducing the dose of each individual agent, thereby improving clinical activity and reducing adverse side effects compared to monotherapy
2Reliability
If current single-agent therapies are used for RAS-mutant cancers, then treatment is simpler, but durable and sustained responses are not achieved
Solution Approach 1:
The patent employs combination therapy with a selective RAF inhibitor and a MEK inhibitor to achieve durable and sustained responses in RAS-mutant cancers. By targeting two different nodes in the RAS/RAF/MEK/ERK signaling pathway simultaneously, the combination prevents adaptive resistance and achieves more持久 therapeutic effects compared to single-agent therapy, despite the increased complexity of the treatment regimen
3Reliability
If RAF inhibitors are used to target BRAF-mutant tumors, then anti-tumor effect is achieved, but resistance develops and clinical activity is limited in RAS-mutant tumors
Solution Approach 1:
The patent uses a selective RAF inhibitor (Compound of formula (I) or (II)) that can inhibit both BRAF and CRAF, combined with a MEK inhibitor (trametinib). This combination creates a universal therapy that is effective across multiple mutation types including BRAF-mutant, KRAS-mutant, and NRAS-mutant tumors. The dual-target approach allows the therapy to adapt to different molecular subtypes by blocking parallel signaling pathways that may be activated in response to single-agent therapy
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a MEK inhibitor, particularly trametinib, particularly for use in the treatment of a proliferative disease. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a proliferative disease; methods of treating a proliferative disease in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; use of such combination for the treatment of proliferative disease; pharmaceutical compositions comprising such combination and commercial packages thereto.